KRONOS BIO INC. - COM

Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform

08 11 2021 15:44:44 提供 Nasdaq GlobeNewswire

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021

30 9 2021 15:35:57 提供 Nasdaq GlobeNewswire

Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations

14 9 2021 07:00:02 提供 Nasdaq GlobeNewswire

Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference 

07 9 2021 06:00:01 提供 Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results

12 8 2021 15:05:01 提供 Nasdaq GlobeNewswire

Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)

27 7 2021 07:00:05 提供 Nasdaq GlobeNewswire

Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today

25 5 2021 07:00:03 提供 Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day

11 5 2021 15:05:01 提供 Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

06 5 2021 07:00:02 提供 Nasdaq GlobeNewswire

Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021

10 4 2021 07:30:00 提供 Nasdaq GlobeNewswire

Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.

31 3 2021 10:25:04 提供 Nasdaq GlobeNewswire

Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors

26 3 2021 07:00:00 提供 Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

23 3 2021 15:05:00 提供 Nasdaq GlobeNewswire

Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

10 3 2021 15:35:00 提供 Nasdaq GlobeNewswire

Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)

04 3 2021 06:00:01 提供 Nasdaq GlobeNewswire

Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

25 2 2021 07:00:01 提供 Nasdaq GlobeNewswire

Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

26 1 2021 07:00:02 提供 Nasdaq GlobeNewswire